Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(1.11)
# 3,549
Out of 4,874 analysts
29
Total ratings
36%
Success rate
-12.22%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRQR ProQR Therapeutics | Initiates: Outperform | $5 | $2.26 | +121.24% | 1 | Apr 29, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $204 → $205 | $185.24 | +10.67% | 3 | Apr 28, 2025 | |
| MNMD Mind Medicine (MindMed) | Initiates: Outperform | $23 | $6.65 | +245.86% | 1 | Jan 28, 2025 | |
| CABA Cabaletta Bio | Downgrades: In-Line | $15 → $6 | $1.66 | +261.45% | 2 | Dec 20, 2024 | |
| ARGX argenx SE | Maintains: Outperform | $675 → $706 | $561.55 | +25.72% | 4 | Nov 21, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $179 → $170 | $17.10 | +894.15% | 9 | Nov 7, 2024 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $65 | $5.70 | +1,040.35% | 2 | Aug 26, 2024 | |
| FHTX Foghorn Therapeutics | Initiates: Outperform | $20 | $4.84 | +313.22% | 1 | Aug 19, 2024 | |
| KRYS Krystal Biotech | Maintains: Outperform | $201 → $206 | $139.55 | +47.62% | 1 | Aug 12, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $62 → $66 | $51.03 | +29.34% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $1.46 | +1,406.85% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $10 | $1.47 | +580.27% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $14.51 | +313.51% | 1 | Oct 5, 2022 |
ProQR Therapeutics
Apr 29, 2025
Initiates: Outperform
Price Target: $5
Current: $2.26
Upside: +121.24%
AbbVie
Apr 28, 2025
Maintains: Outperform
Price Target: $204 → $205
Current: $185.24
Upside: +10.67%
Mind Medicine (MindMed)
Jan 28, 2025
Initiates: Outperform
Price Target: $23
Current: $6.65
Upside: +245.86%
Cabaletta Bio
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $1.66
Upside: +261.45%
argenx SE
Nov 21, 2024
Maintains: Outperform
Price Target: $675 → $706
Current: $561.55
Upside: +25.72%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $17.10
Upside: +894.15%
Jasper Therapeutics
Aug 26, 2024
Maintains: Outperform
Price Target: $65
Current: $5.70
Upside: +1,040.35%
Foghorn Therapeutics
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $4.84
Upside: +313.22%
Krystal Biotech
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $139.55
Upside: +47.62%
Mirum Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $62 → $66
Current: $51.03
Upside: +29.34%
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $1.46
Upside: +1,406.85%
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $1.47
Upside: +580.27%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $14.51
Upside: +313.51%